223 related articles for article (PubMed ID: 25771905)
1. Persistent quality of life impairments in differentiated thyroid cancer patients: results from a monitoring programme.
Gamper EM; Wintner LM; Rodrigues M; Buxbaum S; Nilica B; Singer S; Giesinger JM; Holzner B; Virgolini I
Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1179-88. PubMed ID: 25771905
[TBL] [Abstract][Full Text] [Related]
2. Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial.
Heutte N; Flechtner HH; Mounier N; Mellink WA; Meerwaldt JH; Eghbali H; van't Veer MB; Noordijk EM; Kluin-Nelemans JC; Lampka E; Thomas J; Lugtenburg PJ; Viterbo L; Carde P; Hagenbeek A; van der Maazen RW; Smit WG; Brice P; van Marwijk Kooy M; Baars JW; Poortmans P; Tirelli U; Leeksma OC; Tomsic R; Feugier P; Salles G; Gabarre J; Kersten MJ; Van Den Neste E; Creemers GJ; Gaillard I; Meijnders P; Tertian G; Reman O; Muller HP; Troncy J; Blanc M; Schroyens W; Voogt PJ; Wijermans P; Rieux C; Fermé C; Henry-Amar M;
Lancet Oncol; 2009 Dec; 10(12):1160-70. PubMed ID: 19828373
[TBL] [Abstract][Full Text] [Related]
3. Health status of Greek thyroid cancer patients after radioiodine administration compared to a demographically matched general population sample.
Karapanou O; Papadopoulos A; Vlassopoulou B; Vassilopoulos C; Pappa E; Tsagarakis S; Niakas D
Hell J Nucl Med; 2012; 15(2):98-102. PubMed ID: 22741146
[TBL] [Abstract][Full Text] [Related]
4. Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous and exogenous TSH stimulation.
Vrachimis A; Schober O; Riemann B
Nuklearmedizin; 2012; 51(3):67-72. PubMed ID: 22294096
[TBL] [Abstract][Full Text] [Related]
5. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
[TBL] [Abstract][Full Text] [Related]
6. Difficulties in deciding whether to ablate patients with putatively "low-intermediate-risk" differentiated thyroid carcinoma: do guidelines mainly apply in the centres that produce them? Results of a retrospective, two-centre quality assurance study.
Frangos S; Iakovou IP; Marlowe RJ; Eftychiou N; Patsali L; Vanezi A; Savva A; Mpalaris V; Giannoula EI
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):2045-55. PubMed ID: 26231351
[TBL] [Abstract][Full Text] [Related]
7. Treatment for microcarcinoma of the thyroid--clinical experience.
Küçük NO; Tari P; Tokmak E; Aras G
Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573
[TBL] [Abstract][Full Text] [Related]
8. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F
Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638
[TBL] [Abstract][Full Text] [Related]
9. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
10. Differentiated thyroid cancer in a Swedish county--long-term results and quality of life.
Malterling RR; Andersson RE; Falkmer S; Falkmer U; Niléhn E; Järhult J
Acta Oncol; 2010 May; 49(4):454-9. PubMed ID: 20092427
[TBL] [Abstract][Full Text] [Related]
11. Differentiated thyroid cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4).
Farahati J; Reiners C; Stuschke M; Müller SP; Stüben G; Sauerwein W; Sack H
Cancer; 1996 Jan; 77(1):172-80. PubMed ID: 8630926
[TBL] [Abstract][Full Text] [Related]
12. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
Jarzab B; Handkiewicz-Junak D; Wloch J
Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality of life of thyroid cancer patients undergoing radioiodine therapy: a cohort real-world study in a reference public cancer hospital in Brazil.
Ramim JE; Cardoso MAS; de Oliveira GLC; Gomes ML; Guimarães TT; de Mello RCR; Bergmann A; Pujatti PB
Support Care Cancer; 2020 Aug; 28(8):3771-3779. PubMed ID: 31832820
[TBL] [Abstract][Full Text] [Related]
14. Impact of early vs late postoperative radioiodine remnant ablation on final outcome in patients with low-risk well-differentiated thyroid cancer.
Tsirona S; Vlassopoulou V; Tzanela M; Rondogianni P; Ioannidis G; Vassilopoulos C; Botoula E; Trivizas P; Datseris I; Tsagarakis S
Clin Endocrinol (Oxf); 2014 Mar; 80(3):459-63. PubMed ID: 23895145
[TBL] [Abstract][Full Text] [Related]
15. Combined use of radioiodine therapy and radiofrequency ablation in treating postsurgical thyroid remnant of differentiated thyroid carcinoma.
Long B; Li L; Yao L; Chen S; Yi H; Ye X; Xu D; Wu P
J Cancer Res Ther; 2015 Nov; 11 Suppl():C244-7. PubMed ID: 26612446
[TBL] [Abstract][Full Text] [Related]
16. Health-Related Quality of Life of Community Thyroid Cancer Survivors in Hangzhou, China.
Wang T; Jiang M; Ren Y; Liu Q; Zhao G; Cao C; Wang H
Thyroid; 2018 Aug; 28(8):1013-1023. PubMed ID: 29808769
[TBL] [Abstract][Full Text] [Related]
17. Quality of life in patients with benign nontoxic goiter: impact of disease and treatment response, and comparison with the general population.
Cramon P; Bonnema SJ; Bjorner JB; Ekholm O; Feldt-Rasmussen U; Frendl DM; Groenvold M; Hegedüs L; Rasmussen ÅK; Watt T
Thyroid; 2015 Mar; 25(3):284-91. PubMed ID: 25602312
[TBL] [Abstract][Full Text] [Related]
18. The assessment of health-related quality of life and related factors in Chinese elderly patients undergoing chemotherapy for advanced cancer: a cross-sectional study.
Li Q; Lin Y; Qiu Y; Gao B; Xu Y
Eur J Oncol Nurs; 2014 Aug; 18(4):425-35. PubMed ID: 24721179
[TBL] [Abstract][Full Text] [Related]
19. Health-related quality of life in long-term follow-up of patients with cured TNM Stage I or II differentiated thyroid carcinoma.
Pelttari H; Sintonen H; Schalin-Jäntti C; Välimäki MJ
Clin Endocrinol (Oxf); 2009 Mar; 70(3):493-7. PubMed ID: 18681857
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human thyrotropin versus thyroid hormone withdrawal in radioiodine remnant ablation for differentiated thyroid cancer: a meta-analysis.
Fu H; Ma C; Tang L; Wu F; Liu B; Wang H
Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):121-8. PubMed ID: 24844252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
